✦ LIBER ✦

What is the precancerous lesion for hepatocelluiar carcinoma in man?

✍ Scribed by KUNIO OKUDA

Book ID: 118703660
Publisher: John Wiley and Sons
Year: 1986
Tongue: English
Weight: 514 KB
Volume: 1
Category: Article
ISSN: 0815-9319
DOI: 10.1111/j.1440-1746.1986.tb01760.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

What is the evidence for an organic lesi

What is the evidence for an organic lesion in whiplash injury?

✍ Martin F. Gargan 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 283 KB

Breast conservation for ductal carcinoma

Breast conservation for ductal carcinoma In Situ: What is the risk?

✍ Monica Morrow 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 256 KB

Cytogenetic evidence that carcinoma in s

Cytogenetic evidence that carcinoma in situ is the precursor lesion for invasive testicular germ cell tumors

✍ Jannie van Echten; Marian Stoepker; Beike Leegte; Leendert Looijenga; Bauke de J 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 86 KB

What is the best staging system for hepa

What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?

✍ Kim M. Olthoff; Alejandro Forner; Stefan Hübscher; John Fung 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

The purposes of cancer staging are (1) to accurately predict a patient's prognosis and (2) to determine the appropriate interventions. Hepatocellular carcinoma (HCC) is somewhat unique: it usually affects patients with underlying liver disease, and both tumor burden and liver function need to be car

Heterogeneous amplification of ERBB2 in

Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma

✍ Min A Kim; Hyuk-Joon Lee; Han-Kwang Yang; Yung-Jue Bang; Woo Ho Kim 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 526 KB

Zoledronic acid is superior to pamidrona

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

✍ Lee S. Rosen; David H. Gordon; William Dugan Jr.; Pierre Major; Peter D. Eisenbe 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

## Abstract ## BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial. ## METHODS Overall, 1130 patients with breast carcinoma who